Drugs in Clinical Pipeline: THR-317 I Monoclonal Antibody (mAbs) I Angiogenesis Inhibitors | Placenta Growth Factor (PIGF) Inhibitors | Eye Disorder Therapies

THR-317 (also known as TB-403; RO5323441; αPIGF) is a humanized recombinant immunoglobulin (Ig) G₁ monoclonal antibody directed to the receptor-binding site of placental growth factor (PlGF). Inhibition of angiogenesis as a therapeutic strategy in oncology has been validated by treatments that block VEGF or its receptors, vascular endothelial growth factor receptor (VEGFR-1, -2, -3). Several antiangiogenesis inhibitors targeting VEGF or its receptors have been approved, such as the monoclonal antibody bevacizumab and the tyrosine kinase inhibitors Sorafenib and Sunitinib [1, 2].